Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada · Delayed Price · Currency is CAD 12.35
-0.15 (-1.20%)
Jan 22, 2026, 2:51 PM EST
Eupraxia Pharmaceuticals Market Cap
Eupraxia Pharmaceuticals has a market cap or net worth of CAD 633.1 million as of January 22, 2026. Its market cap has increased by 319.16% in one year.
Market Cap
633.10M
Enterprise Value
551.39M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
12.35
Market Cap Chart
Since March 9, 2021, Eupraxia Pharmaceuticals's market cap has increased from 78.01M to 633.10M, an increase of 711.60%. That is a compound annual growth rate of 53.66%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 21, 2026 | 633.10M | 21.12% |
| Dec 31, 2025 | 522.69M | 225.34% |
| Dec 31, 2024 | 160.66M | 9.74% |
| Dec 29, 2023 | 146.40M | 85.76% |
| Dec 30, 2022 | 78.81M | 125.87% |
| Dec 31, 2021 | 34.89M | -55.27% |
| Mar 9, 2021 | 78.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Bright Minds Biosciences | 1.11B |
| NervGen Pharma | 574.27M |
| Helix BioPharma | 165.74M |
| Satellos Bioscience | 165.10M |
| ME Therapeutics Holdings | 90.15M |
| Medicenna Therapeutics | 75.08M |
| Sharp Therapeutics | 72.18M |
| NurExone Biologic | 59.85M |